NCT05824975 2024-11-25A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)GI Innovation, Inc.Phase 1/2 Recruiting358 enrolled
NCT03530397 2024-06-24A Study to Evaluate MEDI5752 in Subjects With Advanced Solid TumorsMedImmune LLCPhase 1 Active not recruiting401 enrolled